Combination therapy with olmesartan medoxomil and hydrochlorothiazide: Secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study

American Journal of Cardiovascular Drugs

Volumn 9, Issue 4, 2009, Pages 241-251

  Chrysant, Steven G ^a,c   Chavanu, Kathleen J ^b   Xu, Jianbo ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b DAIICHI SANKYO INC   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 70349151351     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200909040-00001     Document Type: Article

References (34)

1. Conen D, Ridker PM, Buring JE, et al. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ 2007; 335 (7617): 432
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903-1913
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351 (9118): 1755-1762
4. Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-2572
5. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49 (1): 69-75
6. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328 (13): 914-921
7. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6 Suppl. 2: S19-21
8. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6 (10): 569-577
9. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4 (6): 393-404
10. Faulkner MA, Hilleman DE. Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin Pharmacother 2001; 2 (1): 165-178
11. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25 (9): 1751-1762
12. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12 (8 Pt 1): 797-805
13. Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002; 9: 111-117
14. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23 (6): 833-850
15. Ohman KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000; 9 (4): 214-220
16. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18 (4): 608-625
17. Ruilope L, Simpson R, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5 (1): 32-40
18. Sachse A, Verboom CN, Jager B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002; 16 (3): 169-176
19. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-259
20. OLMETEC film-coated tablets. In: eMC. Surrey: Datapharm Communications Ltd, 2009 [online]. Available from URL: http://emc.medicines.org.uk/ medicine/15152/SPC/OLMETEC%20film-coated%20tablets/ [Accessed 2009 Jun 18]
21. Benicar® tablets [prescribing information]. Parsippany (NJ): Daiichi Sankyo, Inc. [online]. Available from URL: http://www.benicar.com/pdf/ prescribing-information.pdf [Accessed 2009 Jun 18]
22. Neutel JM, Elliott WJ, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002; 4: 325-331
23. Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23 (11): 2083-2092
24. Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002; 24 (7): 1049-1061
25. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006; 8 (12): 850-87; quiz 8-9
26. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006; 23 (5): 680-695
27. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-tomoderate hypertension. J Hum Hypertens 2003; 17 (6): 425-432
28. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50
29. Hyzaar® (losartan/HCTZ tablets) [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc. [online]. Available from URL: http://www. merck.com/product/usa/pi-circulars/h/hyzaar/hyzaar-pi.pdf [Accessed 2009 Jun 18]
30. Avalide® (irbesartan-hydrochlorothiazide) [prescribing information]. Princeton (NJ): Bristol-Myers Squibb Company [online]. Available from URL: http://packageinserts.bms.com/pi/pi-avalide.pdf [Accessed 2009 Jun 18]
31. Diovan HCT (valsartan and hydrochlorothiazide USP) tablets [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation [online]. Available from URL: http://www.pharma.us.novartis.com/product/ pi/pdf/diovan-hct.pdf [Accessed 2009 Jun 18]
32. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens 2008; 10: 911-921
33. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7 (3): 229-239
34. Izzo JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007; 9: 36-44